US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Gyre Therapeutics

6.36

-0.1100-1.70%

Post-market: 6.360.00000.00%16:10 EDT

Volume:58.06K

Turnover:373.22K

Market Cap:709.20M

PE:-33.42

High:6.67

Open:6.41

Low:6.34

Close:6.47

52wk High:9.42

52wk Low:5.44

Shares:111.51M

Float Shares:35.93M

Volume Ratio:1.43

T/O Rate:0.16%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.1903

EPS(LYR):0.0225

ROE:-17.44%

ROA:-5.42%

PB:6.57

PE(LYR):282.87

Loading ...

Overview Company News Filings

Gyre Therapeutics Outlines Protein Degrader Pipeline, China Commercial Outlook in Corporate Presentation

Gyre Therapeutics unveils capital-efficient global development strategy

Gyre Therapeutics Forecasts FY26 Etuary Revenue at $100.5 Million-$111 Million

Gyre Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Tonix Q2 Revenue Rises Sharply on Tonmya Launch

Axsome Therapeutics Q2 Revenue Rises on Auvelity Growth

H.C. Wainwright Sticks to Its Buy Rating for Gyre Therapeutics (GYRE)

Gyre Therapeutics, Inc. Expected to Post a Loss of 13 Cents a Share - Earnings Preview

Gyre Therapeutics Q2 EPS $(0.12) Misses $(0.04) Estimate, Sales $29.105M Beat $26.490M Estimate

Benzinga Earnings

Gyre Therapeutics Q2 Revenue Beats Estimates on Higher Etuary Sales Volumes

Gyre Therapeutics Q2 2026 Net Loss Widens to $14.3 Million; Revenue Falls 2% to $29.1 Million

Gyre Therapeutics, - Affirms Fy2026 Revenue Guidance of $100.50 Mln-$111 Mln

THOMSON REUTERS

Gyre Therapeutics Q2 Operating Profit USD -14.363 Million

THOMSON REUTERS

Press Release: Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update

Gyre Therapeutics Director Kirkby Maxwell Files Initial Beneficial Ownership Statement

Gyre Therapeutics Adds CSO Yue Xiong, Max Kirkby, Claire Weston to Board Effective Aug. 1

Gyre Therapeutics Appoints Three New Members to Its Board of Directors

THOMSON REUTERS

Gyre Therapeutics Appoints Three New Members to its Board of Directors

GNI’s Gyre Therapeutics files Form S-3 tied to Cullgen acquisition

Gyre Therapeutics files to sell 30.22M shares of common stock for holders

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/GYRE/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GYRE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GYRE\",,,,,undefined,":{"symbol":"GYRE","market":"US","secType":"STK","nameCN":"Gyre Therapeutics","latestPrice":6.36,"timestamp":1788379200000,"preClose":6.47,"halted":0,"volume":58060,"hourTrading":{"tag":"盘后","latestPrice":6.36,"preClose":6.36,"latestTime":"16:10 EDT","volume":1829,"amount":11632.44,"timestamp":1788379804851,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.01700154559505401,"floatShares":35934500,"shares":111509800,"eps":-0.190324,"marketStatus":"Post-Mkt","change":-0.11,"latestTime":"09-02 18:30:12 EDT","open":6.41,"high":6.67,"low":6.3372,"amount":373215,"amplitude":0.051437,"askPrice":6.8,"askSize":20,"bidPrice":5.79,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.190324,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788393600000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":6.47,"preHourTrading":{"tag":"盘前","latestPrice":6.47,"preClose":6.47,"latestTime":"09:25 EDT","volume":4,"amount":25.88,"timestamp":1788355532163,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":6.36,"preClose":6.36,"latestTime":"16:10 EDT","volume":1829,"amount":11632.44,"timestamp":1788379804851,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.425926,"impliedVol":1.7029,"impliedVolPercentile":0.8611},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GYRE\",,,,,undefined,":{"symbol":"GYRE","floatShares":35934500,"roa":"-5.42%","roe":"-17.44%","lyrEps":0.022484,"volumeRatio":1.425926,"shares":111509800,"dividePrice":0,"high":6.67,"amplitude":0.051437,"preClose":6.47,"low":6.3372,"week52Low":5.44,"pbRate":"6.57","psRate":"6.46","week52High":9.42,"institutionHeld":0.2764,"latestPrice":6.36,"committee":0.666667,"eps":-0.190324,"divideRate":0,"volume":58060,"delay":0,"ttmEps":-0.190324,"open":6.41,"prevYearClose":7.06,"prevWeekClose":6.59,"prevMonthClose":6.57,"prevQuarterClose":6.59,"fiveDayClose":6.65,"twentyDayClose":6.23,"sixtyDayClose":6.05},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GYRE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"GYRE","fiscalQuarterEnding":"2026/06","expectedEps":-0.08,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"pre","actualEps":-0.12},{"market":"US","date":"2026-05-07","symbol":"GYRE","fiscalQuarterEnding":"2026/03","expectedEps":-0.06,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"pre","actualEps":-0.08},{"market":"US","date":"2026-03-12","symbol":"GYRE","fiscalQuarterEnding":"2025/12","expectedEps":0.08,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1773288000000,"reportTimeType":"pre","actualEps":0.04},{"market":"US","date":"2025-11-07","symbol":"GYRE","fiscalQuarterEnding":"2025/09","expectedEps":0.05,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762491600000,"reportTimeType":"pre","actualEps":0.05},{"market":"US","date":"2025-08-11","symbol":"GYRE","fiscalQuarterEnding":"2025/06","expectedEps":0.03,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754884800000,"reportTimeType":"post","actualEps":0.02}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GYRE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GYRE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1760155200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GYRE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GYRE","date":"2026-09-01","current":-33.574326,"percent":0.195578,"low":-11548.718266,"twenty":-32.602728,"median":-9.652614,"eighty":115.68348,"high":193.429414,"avg":-540.923701,"sd":2271.881648,"marketCap":696641822},"quantilePoints":[{"date":"2024-04-05","current":-15.607876,"twenty":-15.830217,"median":-15.617068,"eighty":-15.398378,"marketCap":1450486717},{"date":"2024-04-12","current":-31.76291,"twenty":-32.589325,"median":-21.429161,"eighty":-15.61523,"marketCap":1405212396},{"date":"2024-04-19","current":-29.754799,"twenty":-32.477335,"median":-30.585076,"eighty":-15.742078,"marketCap":1316372220},{"date":"2024-04-26","current":-31.531205,"twenty":-31.948274,"median":-30.797472,"eighty":-16.000876,"marketCap":1394961607},{"date":"2024-05-03","current":-27.239192,"twenty":-31.948274,"median":-30.778163,"eighty":-24.631989,"marketCap":1205080075},{"date":"2024-05-10","current":-14.851474,"twenty":-31.774495,"median":-30.223912,"eighty":-24.631989,"marketCap":1301657414},{"date":"2024-05-17","current":-14.909982,"twenty":-31.744918,"median":-29.754799,"eighty":-15.561911,"marketCap":1306785414},{"date":"2024-05-24","current":-12.302842,"twenty":-31.573048,"median":-28.630129,"eighty":-14.89828,"marketCap":1078282562},{"date":"2024-05-31","current":-8605.737804,"twenty":-32.075712,"median":-29.501562,"eighty":-15.108912,"marketCap":890160307},{"date":"2024-06-07","current":-8895.075775,"twenty":-32.90985,"median":-30.136978,"eighty":-15.311743,"marketCap":920088848},{"date":"2024-06-14","current":-9126.546144,"twenty":-8519.763095,"median":-30.585076,"eighty":-15.366351,"marketCap":944031680},{"date":"2024-06-21","current":-8961.210165,"twenty":-8885.155616,"median":-30.816781,"eighty":-15.424018,"marketCap":926929657},{"date":"2024-06-28","current":-8175.864257,"twenty":-8865.315298,"median":-30.894016,"eighty":-15.515947,"marketCap":845695047},{"date":"2024-07-05","current":-9688.68848,"twenty":-8961.210165,"median":-31.531205,"eighty":-15.611553,"marketCap":1002178559},{"date":"2024-07-12","current":-10424.433593,"twenty":-9151.346542,"median":-31.791873,"eighty":-15.679573,"marketCap":1078282562},{"date":"2024-07-15","current":-11094.044316,"twenty":-9210.867496,"median":-31.820836,"eighty":-15.710825,"marketCap":1147545756},{"date":"2024-08-02","current":-11548.718266,"twenty":-9298.495565,"median":-32.139431,"eighty":-15.742078,"marketCap":1194576320},{"date":"2024-08-09","current":-8374.267436,"twenty":-9189.373818,"median":-32.728348,"eighty":-16.000876,"marketCap":866217475},{"date":"2024-08-16","current":-10.635127,"twenty":-9134.812943,"median":-32.641458,"eighty":-15.61523,"marketCap":914301855},{"date":"2024-08-23","current":-11.421808,"twenty":-9126.546144,"median":-31.820836,"eighty":-15.175222,"marketCap":981932798},{"date":"2024-08-30","current":-13.672312,"twenty":-9020.73112,"median":-31.635813,"eighty":-14.375603,"marketCap":1175408659},{"date":"2024-09-06","current":-11.770337,"twenty":-8974.437045,"median":-30.942288,"eighty":-13.816505,"marketCap":1011895874},{"date":"2024-09-13","current":-14.920484,"twenty":-8961.210165,"median":-30.778163,"eighty":-13.696211,"marketCap":1282714046},{"date":"2024-09-20","current":-15.572509,"twenty":-8941.369845,"median":-30.223912,"eighty":-13.816505,"marketCap":1338768556},{"date":"2024-09-27","current":-13.909847,"twenty":-8923.182886,"median":-29.754799,"eighty":-13.90034,"marketCap":1195829555},{"date":"2024-10-04","current":-13.312158,"twenty":-8919.876167,"median":-28.630129,"eighty":-13.654308,"marketCap":1144446254},{"date":"2024-10-11","current":-12.327984,"twenty":-8904.995932,"median":-26.800559,"eighty":-13.325198,"marketCap":1059836795},{"date":"2024-10-18","current":-15.235629,"twenty":-8865.315298,"median":-15.915547,"eighty":-13.300875,"marketCap":1309807059},{"date":"2024-10-25","current":-15.300832,"twenty":-8830.594739,"median":-15.607876,"eighty":-13.325198,"marketCap":1315412510},{"date":"2024-10-31","current":-15.985457,"twenty":-8804.140979,"median":-15.617068,"eighty":-13.405529,"marketCap":1374269746},{"date":"2024-11-08","current":-16.365804,"twenty":-8779.340581,"median":-15.748988,"eighty":-13.558712,"marketCap":1406968211},{"date":"2024-11-15","current":-13.372591,"twenty":-8709.89947,"median":-15.77333,"eighty":-13.558712,"marketCap":1187780244},{"date":"2024-11-22","current":-11.353175,"twenty":-8602.431085,"median":-15.627389,"eighty":-13.295234,"marketCap":1008411696},{"date":"2024-11-29","current":-12.087508,"twenty":-8556.137012,"median":-15.590193,"eighty":-13.126615,"marketCap":1073636622},{"date":"2024-12-06","current":-10.111572,"twenty":-8387.494312,"median":-15.378053,"eighty":-12.781935,"marketCap":898130076},{"date":"2024-12-13","current":-9.449706,"twenty":-8374.267436,"median":-15.329691,"eighty":-12.475931,"marketCap":839341820},{"date":"2024-12-20","current":-10.299987,"twenty":-8344.506959,"median":-15.279098,"eighty":-12.329976,"marketCap":914865419},{"date":"2024-12-27","current":-12.686569,"twenty":-8225.465052,"median":-15.246496,"eighty":-12.302842,"marketCap":1126846431},{"date":"2025-01-03","current":-11.594732,"twenty":-8192.397854,"median":-15.235629,"eighty":-12.152426,"marketCap":1029867264},{"date":"2025-01-10","current":-9.29511,"twenty":-8179.170976,"median":-15.105225,"eighty":-11.98162,"marketCap":825610256},{"date":"2025-01-17","current":-10.435259,"twenty":-3290.168076,"median":-14.953086,"eighty":-11.68749,"marketCap":926880537},{"date":"2025-01-24","current":-10.242013,"twenty":-32.95233,"median":-14.893499,"eighty":-11.536758,"marketCap":909716083},{"date":"2025-01-31","current":-11.111618,"twenty":-32.786274,"median":-14.681409,"eighty":-11.380628,"marketCap":986956128},{"date":"2025-02-07","current":-12.319402,"twenty":-32.658836,"median":-14.539395,"eighty":-11.347378,"marketCap":1094233968},{"date":"2025-02-14","current":-11.382162,"twenty":-32.515952,"median":-14.451664,"eighty":-11.279742,"marketCap":1010986364},{"date":"2025-02-21","current":-12.135819,"twenty":-32.330588,"median":-14.072853,"eighty":-11.345445,"marketCap":1077927736},{"date":"2025-02-28","current":-10.90871,"twenty":-31.809251,"median":-13.976035,"eighty":-11.179254,"marketCap":968933450},{"date":"2025-03-07","current":-10.338636,"twenty":-31.758412,"median":-13.909847,"eighty":-11.12128,"marketCap":918298310},{"date":"2025-03-14","current":-11.556083,"twenty":-31.698577,"median":-13.789262,"eighty":-11.11355,"marketCap":1026434373},{"date":"2025-03-21","current":79.165838,"twenty":-31.423076,"median":-13.627303,"eighty":-11.045914,"marketCap":956719157},{"date":"2025-03-28","current":70.412668,"twenty":-30.971251,"median":-13.353241,"eighty":-10.90871,"marketCap":850937097},{"date":"2025-04-04","current":52.673943,"twenty":-30.878569,"median":-13.283951,"eighty":-10.748316,"marketCap":636564605},{"date":"2025-04-11","current":56.469566,"twenty":-30.809057,"median":-13.129602,"eighty":-10.622099,"marketCap":682434702},{"date":"2025-04-17","current":61.504575,"twenty":-30.778163,"median":-12.849861,"eighty":-10.560868,"marketCap":743282789},{"date":"2025-04-25","current":70.645053,"twenty":-30.585076,"median":-12.780906,"eighty":-10.377285,"marketCap":853745471},{"date":"2025-05-02","current":72.449806,"twenty":-30.310846,"median":-12.626921,"eighty":-10.338636,"marketCap":875555902},{"date":"2025-05-09","current":73.535777,"twenty":-30.136978,"median":-12.473999,"eighty":-10.164715,"marketCap":888679866},{"date":"2025-05-16","current":132.923099,"twenty":-29.947887,"median":-12.417259,"eighty":-9.938068,"marketCap":963825388},{"date":"2025-05-23","current":136.20365,"twenty":-29.754799,"median":-12.327984,"eighty":-9.652614,"marketCap":987612669},{"date":"2025-05-30","current":117.840031,"twenty":-29.349619,"median":-12.308068,"eighty":-9.440044,"marketCap":854458067},{"date":"2025-06-06","current":99.64599,"twenty":-28.753768,"median":-12.251767,"eighty":50.257139,"marketCap":722533070},{"date":"2025-06-13","current":100.896253,"twenty":-28.630129,"median":-12.168656,"eighty":56.159719,"marketCap":731598729},{"date":"2025-06-20","current":104.146938,"twenty":-27.795567,"median":-12.087508,"eighty":59.335648,"marketCap":755169444},{"date":"2025-06-27","current":92.269436,"twenty":-26.976012,"median":-11.969641,"eighty":62.92987,"marketCap":669045678},{"date":"2025-07-03","current":101.646411,"twenty":-26.790554,"median":-11.75017,"eighty":66.71,"marketCap":737038125},{"date":"2025-07-11","current":97.645568,"twenty":-23.367997,"median":-11.701017,"eighty":68.524795,"marketCap":708028014},{"date":"2025-07-18","current":92.394462,"twenty":-17.913275,"median":-11.686523,"eighty":70.505622,"marketCap":669952244},{"date":"2025-07-25","current":92.269436,"twenty":-17.24169,"median":-11.594732,"eighty":71.634434,"marketCap":669045678},{"date":"2025-08-01","current":88.143567,"twenty":-16.863516,"median":-11.531927,"eighty":73.525921,"marketCap":639129001},{"date":"2025-08-08","current":90.018962,"twenty":-16.53533,"median":-11.498109,"eighty":77.782591,"marketCap":652727491},{"date":"2025-08-15","current":179.246974,"twenty":-16.326683,"median":-11.42614,"eighty":87.268382,"marketCap":746563646},{"date":"2025-08-22","current":164.643977,"twenty":-16.268001,"median":-11.353175,"eighty":89.218793,"marketCap":685742166},{"date":"2025-08-29","current":180.563196,"twenty":-16.183906,"median":-11.256552,"eighty":90.29402,"marketCap":752045713},{"date":"2025-09-05","current":165.298192,"twenty":-16.049822,"median":-11.217903,"eighty":91.769331,"marketCap":688466969},{"date":"2025-09-12","current":177.074053,"twenty":-16.011538,"median":-11.179254,"eighty":92.594504,"marketCap":737513429},{"date":"2025-09-19","current":167.696978,"twenty":-15.943032,"median":-11.12128,"eighty":93.569709,"marketCap":698457915},{"date":"2025-09-26","current":158.974119,"twenty":-15.763593,"median":-11.111618,"eighty":95.145041,"marketCap":662127204},{"date":"2025-10-03","current":163.989763,"twenty":-15.70726,"median":-11.048813,"eighty":96.920416,"marketCap":683017363},{"date":"2025-10-10","current":155.921118,"twenty":-15.633582,"median":-10.966684,"eighty":99.846032,"marketCap":649411455},{"date":"2025-10-17","current":190.594485,"twenty":-15.61523,"median":-10.876478,"eighty":100.896253,"marketCap":793826030},{"date":"2025-10-24","current":179.472839,"twenty":-15.600803,"median":-10.763776,"eighty":101.646411,"marketCap":747504374},{"date":"2025-10-31","current":166.824692,"twenty":-15.546428,"median":-10.691308,"eighty":105.447211,"marketCap":694824844},{"date":"2025-11-07","current":160.064476,"twenty":-15.429294,"median":-10.618842,"eighty":111.643728,"marketCap":666668543},{"date":"2025-11-14","current":110.418625,"twenty":-15.377823,"median":-10.570531,"eighty":112.102687,"marketCap":734394278},{"date":"2025-11-21","current":102.355879,"twenty":-15.373231,"median":-10.435259,"eighty":110.254637,"marketCap":680768953},{"date":"2025-11-28","current":105.908954,"twenty":-15.35855,"median":-10.377285,"eighty":109.598685,"marketCap":704400452},{"date":"2025-12-05","current":107.958805,"twenty":-15.300832,"median":-10.338636,"eighty":109.462028,"marketCap":718034009},{"date":"2025-12-12","current":107.548834,"twenty":-15.279098,"median":-10.299987,"eighty":109.871999,"marketCap":715307298},{"date":"2025-12-19","current":100.442685,"twenty":-15.279098,"median":-10.179208,"eighty":109.598685,"marketCap":668044300},{"date":"2025-12-26","current":98.256178,"twenty":-15.261711,"median":-10.046352,"eighty":109.489359,"marketCap":653501839},{"date":"2026-01-02","current":96.479641,"twenty":-15.250843,"median":-9.954769,"eighty":109.29804,"marketCap":641686089},{"date":"2026-01-09","current":103.449133,"twenty":-15.243518,"median":-9.652614,"eighty":109.106721,"marketCap":688040184},{"date":"2026-01-16","current":105.22567,"twenty":-15.23799,"median":-9.652614,"eighty":108.560094,"marketCap":699855933},{"date":"2026-01-23","current":110.008655,"twenty":-15.222589,"median":-9.517342,"eighty":109.134052,"marketCap":731667567},{"date":"2026-01-30","current":112.195163,"twenty":-15.163907,"median":-9.314435,"eighty":109.544022,"marketCap":746210028},{"date":"2026-02-06","current":102.629193,"twenty":-15.092184,"median":51.163441,"eighty":109.680679,"marketCap":682586761},{"date":"2026-02-13","current":106.865551,"twenty":-15.037849,"median":54.920332,"eighty":109.544022,"marketCap":710762779},{"date":"2026-02-20","current":115.064954,"twenty":-14.972646,"median":56.469566,"eighty":109.844668,"marketCap":765297008},{"date":"2026-02-27","current":116.431521,"twenty":-14.918384,"median":59.41311,"eighty":110.555282,"marketCap":774386046},{"date":"2026-03-06","current":107.002208,"twenty":-14.903389,"median":60.420111,"eighty":111.484548,"marketCap":711671683},{"date":"2026-03-13","current":141.117848,"twenty":-14.871908,"median":65.067812,"eighty":112.058506,"marketCap":709399423},{"date":"2026-03-20","current":123.520041,"twenty":-14.817461,"median":66.926893,"eighty":112.457994,"marketCap":620935247},{"date":"2026-03-27","current":127.879572,"twenty":-14.672715,"median":68.213723,"eighty":113.15176,"marketCap":642850609},{"date":"2026-04-02","current":131.330867,"twenty":-14.637941,"median":68.717439,"eighty":113.9717,"marketCap":660200270},{"date":"2026-04-10","current":131.512514,"twenty":-14.560386,"median":70.412668,"eighty":115.791328,"marketCap":661113410},{"date":"2026-04-17","current":143.501224,"twenty":-14.518403,"median":70.916169,"eighty":118.208058,"marketCap":721380655},{"date":"2026-04-24","current":135.145457,"twenty":-14.464068,"median":71.829251,"eighty":123.520041,"marketCap":679376212},{"date":"2026-05-01","current":139.504988,"twenty":-14.451664,"median":72.980471,"eighty":126.240493,"marketCap":701291573},{"date":"2026-05-08","current":-107.788052,"twenty":-14.451664,"median":73.535777,"eighty":127.334631,"marketCap":685747587},{"date":"2026-05-15","current":-100.534989,"twenty":-14.637941,"median":72.372236,"eighty":126.808829,"marketCap":639603601},{"date":"2026-05-22","current":-88.758033,"twenty":-14.909982,"median":71.342209,"eighty":126.608042,"marketCap":564678607},{"date":"2026-05-29","current":-82.438691,"twenty":-15.079143,"median":70.645053,"eighty":126.314003,"marketCap":524474952},{"date":"2026-06-05","current":-88.901655,"twenty":-15.242525,"median":70.38405,"eighty":126.098579,"marketCap":565592327},{"date":"2026-06-12","current":-87.034576,"twenty":-15.283445,"median":68.648906,"eighty":126.010611,"marketCap":553713974},{"date":"2026-06-18","current":-87.321819,"twenty":-15.377362,"median":68.088818,"eighty":124.946974,"marketCap":555541413},{"date":"2026-06-26","current":-89.47614,"twenty":-15.611553,"median":66.655777,"eighty":123.810677,"marketCap":569247204},{"date":"2026-07-02","current":-93.641161,"twenty":-15.753857,"median":65.067812,"eighty":123.374723,"marketCap":595745068},{"date":"2026-07-10","current":-120.215892,"twenty":-16.183906,"median":60.420111,"eighty":122.720794,"marketCap":764813504},{"date":"2026-07-17","current":-112.505251,"twenty":-16.863516,"median":59.41311,"eighty":121.124631,"marketCap":715758410},{"date":"2026-07-24","current":-105.320337,"twenty":-26.790554,"median":56.469566,"eighty":119.109992,"marketCap":670047982},{"date":"2026-07-31","current":-101.8155,"twenty":-28.630129,"median":54.920332,"eighty":118.134453,"marketCap":647750212},{"date":"2026-08-07","current":-112.154768,"twenty":-30.09916,"median":51.163441,"eighty":117.790204,"marketCap":713528633},{"date":"2026-08-14","current":-32.674966,"twenty":-30.809057,"median":-9.314435,"eighty":117.359023,"marketCap":693460810},{"date":"2026-08-21","current":-35.073129,"twenty":-31.698577,"median":-9.517342,"eighty":116.303482,"marketCap":744357016},{"date":"2026-08-28","current":-33.37443,"twenty":-32.401491,"median":-9.652614,"eighty":115.755379,"marketCap":708305536},{"date":"2026-09-01","current":-32.824851,"twenty":-32.602728,"median":-9.652614,"eighty":115.68348,"marketCap":696641822}],"updateTime":1788364392850},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GYRE\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664859031","title":"Gyre Therapeutics Outlines Protein Degrader Pipeline, China Commercial Outlook in Corporate Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2664859031","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664859031?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:44","pubTimestamp":1788266658,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics outlines protein degrader pipeline, China commercial outlook in corporate presentationGyre Therapeutics outlined a global development model anchored in China discovery and commercial","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDLbTWZQ7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662712778","title":"Gyre Therapeutics unveils capital-efficient global development strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2662712778","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662712778?lang=en_us&edition=fundamental","pubTime":"2026-08-26 21:28","pubTimestamp":1787750925,"startTime":"0","endTime":"0","summary":"An update from Gyre Therapeutics ( ($GYRE) ) is now available. On August 26, 2026, Gyre Therapeutics released an updated corporate presentation det...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gyre-therapeutics-unveils-capital-efficient-global-development-strategy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gyre-therapeutics-unveils-capital-efficient-global-development-strategy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662144897","title":"Gyre Therapeutics Forecasts FY26 Etuary Revenue at $100.5 Million-$111 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662144897","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662144897?lang=en_us&edition=fundamental","pubTime":"2026-08-26 21:05","pubTimestamp":1787749524,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics forecasts FY26 ETUARY revenue at $100.5 million-$111 millionGyre Therapeutics outlined a strategy to fund targeted protein degrader and degrader antibody-conjugate programs using Chi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL6Sx1bK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658935423","title":"Gyre Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2658935423","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658935423?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:00","pubTimestamp":1786363238,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings SummaryGyre Therapeutics, Inc.GYRE.OQreported a quarterly adjusted loss of 12 cents per share for the quarter ended Jun","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL8N4470S5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658938477","title":"Tonix Q2 Revenue Rises Sharply on Tonmya Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2658938477","media":"Reuters","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658938477?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:11","pubTimestamp":1786360272,"startTime":"0","endTime":"0","summary":"Tonix Q2 revenue rises sharply on TONMYA launchOverviewUS biopharma firm's Q2 net product revenue rose sharply year-over-year, driven by TONMYA launchTONMYA net sales nearly tripled quarter-over-quart","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N44709K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0566484027.USD","LU1559883803.SGD","TNXP","ANIP","GYRE","BK4583","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658938415","title":"Axsome Therapeutics Q2 Revenue Rises on Auvelity Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2658938415","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658938415?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:10","pubTimestamp":1786360249,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics Q2 revenue rises on AUVELITY growthOverviewUS biopharmaceutical firm's Q2 revenue grew 46% yr/yr but missed analyst expectationsNet loss for Q2 widened slightly compared to last ye","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N44709M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4007","LU0566484027.USD","BK4505","BK4539","TMCI","ANIP","AXSM","BK4139","LU1559883803.SGD","GYRE","BK4585","LU2324357040.USD","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657647578","title":"H.C. Wainwright Sticks to Its Buy Rating for Gyre Therapeutics (GYRE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657647578","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657647578?lang=en_us&edition=fundamental","pubTime":"2026-08-07 23:35","pubTimestamp":1786116937,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Matthew Keller reiterated a Buy rating on Gyre Therapeutics today and set a price target of $18.00. Keller covers the Healt...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-buy-rating-for-gyre-therapeutics-gyre-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-buy-rating-for-gyre-therapeutics-gyre-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657642962","title":"Gyre Therapeutics, Inc. Expected to Post a Loss of 13 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2657642962","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657642962?lang=en_us&edition=fundamental","pubTime":"2026-08-07 23:01","pubTimestamp":1786114868,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics, Inc. <GYRE.OQ> expected to post a loss of13cents a share - Earnings PreviewGyre Therapeutics, Inc.GYRE.OQGYRE.Ois expected to  show a fall in quarterly revenue when it reports  resu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N4441SO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657648288","title":"Gyre Therapeutics Q2 EPS $(0.12) Misses $(0.04) Estimate, Sales $29.105M Beat $26.490M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657648288","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657648288?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:39","pubTimestamp":1786102743,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics (NASDAQ:GYRE) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.04) by 200 percent.  The company reported quarterly sales of $29.105 million which beat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61034682/gyre-therapeutics-q2-eps-0-12-misses-0-04-estimate-sales-29-105m-beat-26-490m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657610434","title":"Gyre Therapeutics Q2 Revenue Beats Estimates on Higher Etuary Sales Volumes","url":"https://stock-news.laohu8.com/highlight/detail?id=2657610434","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657610434?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:13","pubTimestamp":1786101215,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics Q2 revenue beats estimates on higher ETUARY sales volumesOverviewUS-China biopharma firm's Q2 revenue fell yr/yr but beat analyst expectationsCompany reported Q2 GAAP net loss widene","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL1N4440CX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0203345920.USD","LU0154245756.USD","GYRE","LU0511384066.AUD","LU0472753341.HKD","BK4567","LU0203347892.USD","LU0069063385.USD","BK4588","BK4149","LU0689626769.HKD","BK4585","CMI","LU0124676726.USD","GLUE","IE000M9KFDE8.USD","ZNTL","LU0154245673.USD","LU0289961442.SGD","LU0057025933.USD","LU2463526074.USD","BK4539","BK4533","BK4139","MADE","LU0289739343.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657105636","title":"Gyre Therapeutics Q2 2026 Net Loss Widens to $14.3 Million; Revenue Falls 2% to $29.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657105636","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657105636?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:04","pubTimestamp":1786100687,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics Q2 2026 net loss widens to $14.3 million; revenue falls 2% to $29.1 millionGyre Therapeutics posted Q2 revenue of USD 29.1 million, down 2% year over year, while GAAP basic EPS widen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDL8SbKmq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00BKPKM429.USD","SG9999014013.SGD","SG9999014021.USD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","GYRE","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","NDAQ","SG9999014005.SGD","BK4585","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","BCDF","BK4112","SG9999014039.USD","BK4139","LU2210149790.SGD","LU2210150020.SGD","LU2095319765.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657761017","title":"Gyre Therapeutics, - Affirms Fy2026 Revenue Guidance of $100.50 Mln-$111 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2657761017","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657761017?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:00","pubTimestamp":1786100401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nPLXCD1ZJH:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657013617","title":"Gyre Therapeutics Q2 Operating Profit USD -14.363 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657013617","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657013617?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:00","pubTimestamp":1786100401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nPLXCD1ZJH:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657610803","title":"Press Release: Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2657610803","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657610803?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:00","pubTimestamp":1786100400,"startTime":"0","endTime":"0","summary":"Q2 2026 revenue of $29.1 million; GAAP basic EPS: $(0.12)Full year 2026 revenue guidance of $100.5 to $111.0 million affirmedNDA for F351 (hydronidone) for CHB-induced liver fibrosis accepted by China","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","LU1169590202.USD","PD","CDE","LU1223083913.SGD","LU1223082196.USD","BK4604","CFO","BK4099","CEO","IND","LU1223082519.USD","TM","BK4585","GYRE","SGDM","CHB","BK4588","BK4139","LU1169589451.USD","XME","BK4555","GDXJ","SIL","BK4023","BK4017"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657320595","title":"Gyre Therapeutics Director Kirkby Maxwell Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2657320595","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657320595?lang=en_us&edition=fundamental","pubTime":"2026-08-05 08:24","pubTimestamp":1785889477,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics director Kirkby Maxwell files initial beneficial ownership statementGyre Therapeutics director Maxwell Kirkby filed an initial Form 3 beneficial ownership statement dated Aug. 1, 202","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL5FxT33:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652244264","title":"Gyre Therapeutics Adds CSO Yue Xiong, Max Kirkby, Claire Weston to Board Effective Aug. 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2652244264","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652244264?lang=en_us&edition=fundamental","pubTime":"2026-07-17 04:07","pubTimestamp":1784232424,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics adds CSO Yue Xiong, Max Kirkby, Claire Weston to board effective Aug. 1Gyre Therapeutics named Yue Xiong, Max Kirkby, Claire Weston to its board, effective Aug. 1, 2026.Xiong, chief ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nNDL8p8LqT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GYRE","LU2089984988.USD","BBH","LU0306807586.USD","LU0553294199.USD","LU0964806797.USD","IE00BKPKM643.USD","LU0949170772.SGD","LU1868836757.USD","PJP","LU0310800965.SGD","BIB","LU0058720904.USD","SG9999001176.SGD","IHE","LU0237698245.USD","LU2237443622.USD","BK4588","PBE","LU2293690249.USD","LU0857590862.USD","BK4581","IE00B3T34201.USD","LU2210149790.SGD","LU2095319765.USD","BMY","LU2133065610.SGD","LU0823399737.USD","IBBQ","LU1718418525.SGD","FTXH","IBB","BCDF","LU1301847155.USD","LU1670710588.SGD","LU1585245621.USD","LU2242652126.USD","LU1571399168.USD","AZN.UK","LU0949170426.SGD","03165","LU0972486137.USD","AMGN","IE00B3QW5Z07.USD","BK4599","LU0859254822.USD","SG9999014039.USD","NDAQ","LU1883839398.USD","IE00BFXG1179.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652424487","title":"Gyre Therapeutics Appoints Three New Members to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2652424487","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652424487?lang=en_us&edition=fundamental","pubTime":"2026-07-17 04:05","pubTimestamp":1784232301,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nTUA9Y9LLK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652839422","title":"Gyre Therapeutics Appoints Three New Members to its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2652839422","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652839422?lang=en_us&edition=fundamental","pubTime":"2026-07-17 04:05","pubTimestamp":1784232300,"startTime":"0","endTime":"0","summary":"SAN DIEGO, July  16, 2026  (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or the “Company”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with ope","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/16/3328792/0/en/Gyre-Therapeutics-Appoints-Three-New-Members-to-its-Board-of-Directors.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4021","CHB","GYRE","DAC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645850556","title":"GNI’s Gyre Therapeutics files Form S-3 tied to Cullgen acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2645850556","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645850556?lang=en_us&edition=fundamental","pubTime":"2026-06-24 07:52","pubTimestamp":1782258736,"startTime":"0","endTime":"0","summary":"GNI Group ( ($JP:2160) ) just unveiled an announcement. GNI Group has announced that its U.S. subsidiary Gyre Therapeutics has filed a Form S-3 reg...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gnis-gyre-therapeutics-files-form-s-3-tied-to-cullgen-acquisition?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gnis-gyre-therapeutics-files-form-s-3-tied-to-cullgen-acquisition?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645880935","title":"Gyre Therapeutics files to sell 30.22M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2645880935","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645880935?lang=en_us&edition=fundamental","pubTime":"2026-06-23 18:06","pubTimestamp":1782209184,"startTime":"0","endTime":"0","summary":"06:03 EDT Gyre Therapeutics (GYRE) files to sell 30.22M shares of common stock for holders Published first on TheFly – the ultimate source for real...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gyre-therapeutics-files-to-sell-30-22m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gyre-therapeutics-files-to-sell-30-22m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":77,"code":"91000000","status":"200"}]}}